Your browser doesn't support javascript.
loading
The Suboptimal Pediatric HIV Viral Load Cascade: Multidistrict Cohort Study Among Children Taking Antiretroviral Therapy in Lesotho, Southern Africa.
Muhairwe, Josephine A; Brown, Jennifer A; Motaboli, Lipontso; Nsakala, Bienvenu L; Lerotholi, Malebanye; Amstutz, Alain; Klimkait, Thomas; Glass, Tracy R; Labhardt, Niklaus D.
Afiliación
  • Muhairwe JA; From the SolidarMed, Partnerships for Health, Maseru, Lesotho.
  • Brown JA; Institute of Global Health, University of Geneva, Geneva, Switzerland.
  • Motaboli L; Department of Medicine, Swiss Tropical & Public Health Institute, Basel, Switzerland.
  • Nsakala BL; Molecular Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.
  • Lerotholi M; University of Basel, Basel, Switzerland.
  • Amstutz A; From the SolidarMed, Partnerships for Health, Maseru, Lesotho.
  • Klimkait T; From the SolidarMed, Partnerships for Health, Maseru, Lesotho.
  • Glass TR; Ministry of Health of Lesotho, Maseru, Lesotho.
  • Labhardt ND; Department of Medicine, Swiss Tropical & Public Health Institute, Basel, Switzerland.
Pediatr Infect Dis J ; 41(3): e75-e80, 2022 03 01.
Article en En | MEDLINE | ID: mdl-34862344
BACKGROUND: Children living with HIV and taking antiretroviral therapy (ART) are a priority group for routine viral load (VL) monitoring. As per Lesotho guidelines, a VL ≥1000 copies/mL ("unsuppressed") should trigger adherence counseling and a follow-up VL; 2 consecutive unsuppressed VLs ("virologic failure") qualify for switching to second-line ART, with some exceptions. Here, we describe the pediatric VL cascade in Lesotho. METHODS: In a prospective open cohort study comprising routine VL results from 22 clinics in Lesotho, we assessed outcomes along the VL cascade for children who had at least 1 VL test from January 2016 through June 2020. Data were censored on February 10, 2021. RESULTS: In total, 1215 children received 5443 VL tests. The median age was 10 years (interquartile range 7-13) and 627/1215 (52%) were female; 362/1215 (30%) had at least 1 unsuppressed VL. A follow-up VL was available for 325/362 (90%), although only for 159/362 (44%) within 6 months of the first unsuppressed VL. Of those with a follow-up VL, 172/329 (53%) had virologic failure and 123/329 (37%) qualified for switching to second-line ART. Of these, 55/123 (45%) were ever switched, although only 9/123 (7%) were switched within 12 weeks of the follow-up VL. Delays were more pronounced in rural facilities. Overall, 100/362 (28%) children with an unsuppressed VL received a timely follow-up VL and, if required, a timely regimen switch. CONCLUSIONS: Despite access to VL monitoring, clinical management was suboptimal. HIV programs should prioritize timely clinical action to maximize the benefits of VL monitoring.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Infecciones por VIH / Fármacos Anti-VIH / Carga Viral Tipo de estudio: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Risk_factors_studies País/Región como asunto: Africa Idioma: En Revista: Pediatr Infect Dis J Asunto de la revista: DOENCAS TRANSMISSIVEIS / PEDIATRIA Año: 2022 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Infecciones por VIH / Fármacos Anti-VIH / Carga Viral Tipo de estudio: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Risk_factors_studies País/Región como asunto: Africa Idioma: En Revista: Pediatr Infect Dis J Asunto de la revista: DOENCAS TRANSMISSIVEIS / PEDIATRIA Año: 2022 Tipo del documento: Article